drugset / Trial / NCT00242528

Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.

NCT00242528

Phase 4 Withdrawn Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of intravenous zoledronic acid in the treatment of patients with multiple myeloma stage III with bone lesions related to Cancer.

Timeline

Start
2004-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified Intravenous

Indications